Adma Biologics, Inc.
A maker of plasma-derived medicines for people with weakened immune systems, ADMA Biologics produces immune globulin therapies such as BIVIGAM and Nabi-HB, used to treat primary immunodeficiency and to guard against hepatitis B. The company was formed in 2013 when ADMA Biologics merged with Nabi Biologics, combining their plasma collection and manufacturing operations. Headquartered in Boca Raton, Florida, it collects plasma and turns it into treatments for immune deficiency patients.
Granted 10.7K · Bought 14.0K
Granted 372.5K · Sold 126.0K
Granted 10.7K · Bought 31.4K
Granted 101.7K · Sold 10.1K
Granted 40.7K
Granted 10.7K
Granted 10.7K
Granted 10.7K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Elms SteveDirector · 3 transactions | — | 6.21M | 10.7K | 14.0K | — |
| Grossman Adam SPresident and CEO, Director · 23 transactions | +2.3% | 3.84M | 372.5K | — | 126.0K |
| Grossman Jerrold BDirector · 4 transactions | +7.4% | 613.0K | 10.7K | 31.4K | — |
| Kestenberg-Messina Kaitlin M.COO and SVP, Compliance · 12 transactions | -8.7% | 446.2K | 101.7K | — | 10.1K |
| Guiheen Lawrence P.Director · 4 transactions | — | 373.0K | 40.7K | — | — |
| Kwon YoungDirector · 1 transaction | +4.2% | 263.0K | 10.7K | — | — |
| Tade Brad L.CFO and Treasurer · 1 transaction | -2.7% | 232.9K | — | — | — |
| Finger Alison CecilyDirector · 1 transaction | +30.6% | 45.6K | 10.7K | — | — |
| Salas Eduardo ReneDirector · 1 transaction | +98.2% | 21.6K | 10.7K | — | — |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over the last year: -90.7K shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.